Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$18.78 USD
+0.46 (2.51%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $18.98 +0.20 (1.06%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.78 USD
+0.46 (2.51%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $18.98 +0.20 (1.06%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 0.00% and 7.44%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Corbus (CRBP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -20.59% and -44.55%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Corbus Pharmaceuticals (CRBP) Q4 Earnings Expected to Decline
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 49.71%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 113.64% and 181.93%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug
by Zacks Equity Research
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -2250.00% and -91.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Corbus (CRBP) This Earnings Season?
by Zacks Equity Research
Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.
What's in Store for Sorrento (SRNE) This Earnings Season?
by Zacks Equity Research
Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.
Corbus Pharmaceuticals (CRBP) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for BioDelivery (BDSI) This Earnings Season?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
What's in the Cards for AEterna (AEZS) This Earnings Season?
by Zacks Equity Research
AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.
All You Need to Know About Corbus Pharmaceuticals (CRBP) Rating Upgrade to Buy
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corbus Pharmaceuticals (CRBP) Stock Moves -1.23%: What You Should Know
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) closed the most recent trading day at $7.23, moving -1.23% from the previous trading session.
Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) closed at $7.18 in the latest trading session, marking a -0.97% move from the prior day.
Is Corbus Pharmaceuticals Holdings (CRBP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CRBP) Outperforming Other Medical Stocks This Year?
Corbus Pharmaceuticals (CRBP) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -36.36% and -3.02%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Corbus (CRBP) This Earnings Season?
by Zacks Equity Research
Corbus (CRBP) is expected to provide updates on its pipeline candidates in the fourth quarter conference call.
Pacira (PCRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) impresses investors with both earnings and revenue beat in the fourth quarter.
Jazz Pharmaceuticals (JAZZ) Surges: Stock Moves 7.9% Higher
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.